A study to measure daridorexant in breast milk of healthy lactating women
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
10
Daridorexant will be available as film-coated tablets for oral administration formulated at a strength of 50 mg.
Labcorp Clinical Research Unit Inc.
Madison, Wisconsin, United States
Milk pharmacokinetic endpoints: Amount of daridorexant excreted (mg)
Cumulative amount excreted in breast milk over the collection time
Time frame: 0 to 72 hours after study treatment administration (Total duration: up to 4 days)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.